Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cetuximab Monotherapy and Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With KRAS- and BRAF Wild-type Metastatic Colorectal Cancer. A Multicenter Phase II Trial

NCT01718808 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT01718808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01718808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cetuximab Monotherapy and Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With KRAS- and BRAF Wild-type Metastatic Colorectal Cancer. A Multicenter Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2012
Completion date
January 31, 2017
Enrollment
24 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer